BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32468640)

  • 21. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
    Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA
    Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence.
    Montemurro F; Del Mastro L; De Laurentiis M; Puglisi F
    Expert Rev Anticancer Ther; 2016; 16(2):211-8. PubMed ID: 26634955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
    Regan MM; Francis PA; Pagani O; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Price KN; Coates AS; Goldhirsch A; Gelber RD
    J Clin Oncol; 2016 Jul; 34(19):2221-31. PubMed ID: 27044936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal women.
    Pritchard K
    Breast Cancer Res; 2005; 7(2):70-6. PubMed ID: 15743514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer.
    Kwon JS; Pansegrau G; Nourmoussavi M; Hammond GL; Carey MS
    J Natl Compr Canc Netw; 2017 Aug; 15(8):1015-1021. PubMed ID: 28784863
    [No Abstract]   [Full Text] [Related]  

  • 27. Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer.
    Bense RD; Qiu SQ; de Vries EGE; Schröder CP; Fehrmann RSN
    Cancer Treat Rev; 2018 Nov; 70():118-126. PubMed ID: 30149225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New insights into endocrine therapy for young women with breast cancer.
    Di Lascio S; Pagani O
    Womens Health (Lond); 2015 Jun; 11(3):343-54. PubMed ID: 26102472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study.
    Ferreira AR; Ribeiro J; Miranda A; Mayer A; Passos-Coelho JL; Brito M; Fernandes J; Gouveia J; Costa L; Vaz-Luis I
    Clin Breast Cancer; 2019 Oct; 19(5):e654-e667. PubMed ID: 31327728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).
    Gori S; Puglisi F; Cinquini M; Pappagallo G; Frassoldati A; Biganzoli L; Cortesi L; Fiorentino A; Angiolini C; Tinterri C; De Censi A; Levaggi A; Del Mastro L
    Eur J Cancer; 2018 Aug; 99():9-19. PubMed ID: 29886394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
    Pagani O; Walley BA; Fleming GF; Colleoni M; Láng I; Gomez HL; Tondini C; Burstein HJ; Goetz MP; Ciruelos EM; Stearns V; Bonnefoi HR; Martino S; Geyer CE; Chini C; Puglisi F; Spazzapan S; Ruhstaller T; Winer EP; Ruepp B; Loi S; Coates AS; Gelber RD; Goldhirsch A; Regan MM; Francis PA;
    J Clin Oncol; 2023 Mar; 41(7):1376-1382. PubMed ID: 36521078
    [No Abstract]   [Full Text] [Related]  

  • 32. Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer.
    Azim HA; Davidson NE; Ruddy KJ
    Am Soc Clin Oncol Educ Book; 2016; 35():23-32. PubMed ID: 27249683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.
    Frampton JE
    Drugs; 2017 Dec; 77(18):2037-2048. PubMed ID: 29177573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controversies in adjuvant endocrine treatment of premenopausal women.
    Goldstein LJ
    Clin Breast Cancer; 2006 Feb; 6 Suppl 2():S36-40. PubMed ID: 16595024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting benefit of endocrine therapy for early breast cancer.
    Regan MM
    Breast; 2015 Nov; 24 Suppl 2(0 2):S129-31. PubMed ID: 26255197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant ovarian suppression in premenopausal breast cancer.
    Francis PA; Regan MM; Fleming GF; Láng I; Ciruelos E; Bellet M; Bonnefoi HR; Climent MA; Da Prada GA; Burstein HJ; Martino S; Davidson NE; Geyer CE; Walley BA; Coleman R; Kerbrat P; Buchholz S; Ingle JN; Winer EP; Rabaglio-Poretti M; Maibach R; Ruepp B; Giobbie-Hurder A; Price KN; Colleoni M; Viale G; Coates AS; Goldhirsch A; Gelber RD; ;
    N Engl J Med; 2015 Jan; 372(5):436-46. PubMed ID: 25495490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer.
    Sukumar JS; Sardesai S; Ni A; Williams N; Johnson K; Quiroga D; Ramaswamy B; Wesolowski R; Cherian M; Stover DG; Gatti-Mays M; Pariser A; Sudheendra P; George MA; Lustberg M
    Cancer Med; 2024 Jun; 13(12):e7317. PubMed ID: 38895891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.
    Carlson RW; Hudis CA; Pritchard KI; ; ;
    J Natl Compr Canc Netw; 2006 Nov; 4(10):971-9. PubMed ID: 17112447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers.
    Vaz-Luis I; Francis PA; Di Meglio A; Stearns V
    Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-15. PubMed ID: 33989019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.